Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 April 2025 | Story Onthatile Tikoe | Photo Onthatile Tikoe
Zane Dippenaar
Dr Zané Dippenaar (30) is the youngest PhD graduate in this year’s Business Management class from the University of the Free State.

Zané Dippenaar, a 30-year-old marketing and project manager at a Cape Town-based solar energy company, is the youngest person in this year’s graduating class to earn a Doctor of Philosophy (PhD) in Business Management degree from the University of the Free State this year.  

But despite this achievement, the newly minted Dr Dippenaar says she would not have predicted she would study her way to PhD level. 

“I wasn’t particularly academically driven before tertiary education, but I knew from early on that I wanted to either become a teacher or pursue something in the world of business,” she says. Her natural ability and her family’s encouragement led her to explore entrepreneurship and marketing, which she soon developed a passion for.

 

Overcoming challenges and finding support

Dr Dippenaar’s academic journey was marked by significant challenges, including balancing work and study commitments. However, she credits her supervisors and family for helping her stay motivated. 

Her dissertation, titled ‘Advertising and Brand Loyalty in the South African Solar Industry’, showcases her expertise in marketing and branding.

“There were moments filled with doubt, setbacks, and exhaustion, but I was fortunate to have a strong support system who continuously encouraged me and reminded me of what I was working towards,” she says.

 

Achieving a personal milestone

Dr Dippenaar’s PhD achievement is not only an academic milestone but also a personal triumph. She had set a goal of completing her PhD before turning 30 and achieved it just weeks before her birthday. “That was a personal milestone I had set for myself, and achieving it was incredibly fulfilling,” she says. 

She plans to apply the knowledge she gained in the industry and potentially return to academia. She advises younger students to trust their instincts and start their academic journey without waiting for perfection.

“Don’t wait until you’re ‘ready’ – you never will be. Just start. Surround yourself with people who believe in you, ask for help when you need it, and take it one chapter at a time,” she advises.

 

A role model for others

Dr Dippenaar hopes to inspire others, particularly young women, by showing that success in academia doesn’t follow a one-size-fits-all formula. “I hope my story demonstrates that with the right support, determination, and a willingness to carve your own path, anything is possible.”

The University of the Free State is proud to have played a role in Dippenaar’s academic journey, fostering her growth and expertise in business management. Her achievement is a testament to the institution’s commitment to academic excellence and innovation.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept